RADEK SKODA to Janus Kinase 2
This is a "connection" page, showing publications RADEK SKODA has written about Janus Kinase 2.
Connection Strength
13.786
-
Loss of Socs2 improves molecular responses to IFNa in a mouse model of myeloproliferative neoplasms driven by JAK2-V617F. Leukemia. 2025 Apr; 39(4):876-887.
Score: 0.861
-
Loss of Dnmt3a increases self-renewal and resistance to pegIFN-a in JAK2-V617F-positive myeloproliferative neoplasms. Blood. 2024 06 13; 143(24):2490-2503.
Score: 0.818
-
The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN. Blood Adv. 2024 05 14; 8(9):2312-2325.
Score: 0.813
-
Inhibition of interleukin-1? reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm. Nat Commun. 2022 09 13; 13(1):5346.
Score: 0.724
-
JAK2-V617F and interferon-a induce megakaryocyte-biased stem cells characterized by decreased long-term functionality. Blood. 2021 04 22; 137(16):2139-2151.
Score: 0.658
-
MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineages. Blood. 2020 11 26; 136(22):2591-2595.
Score: 0.639
-
JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms. Blood. 2019 11 21; 134(21):1832-1846.
Score: 0.596
-
Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis. J Exp Med. 2016 07 25; 213(8):1479-96.
Score: 0.472
-
JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis. Blood. 2016 08 11; 128(6):839-51.
Score: 0.469
-
Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN. Blood. 2015 Mar 26; 125(13):2131-40.
Score: 0.426
-
Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F. J Exp Med. 2014 Oct 20; 211(11):2213-30.
Score: 0.418
-
Less Jak2 makes more platelets. Blood. 2014 Oct 02; 124(14):2168-9.
Score: 0.417
-
Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs. Blood. 2014 Jun 19; 123(25):3943-50.
Score: 0.406
-
Selective deletion of Jak2 in adult mouse hematopoietic cells leads to lethal anemia and thrombocytopenia. Haematologica. 2014 Apr; 99(4):e52-4.
Score: 0.399
-
Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model. Blood. 2013 Feb 14; 121(7):1188-99.
Score: 0.369
-
Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood. 2010 Mar 11; 115(10):2003-7.
Score: 0.301
-
Thrombocytosis. Hematology Am Soc Hematol Educ Program. 2009; 159-67.
Score: 0.280
-
Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. Blood. 2009 Feb 26; 113(9):2022-7.
Score: 0.279
-
The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders. Haematologica. 2008 Dec; 93(12):1890-3.
Score: 0.274
-
Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations. Blood. 2008 Apr 01; 111(7):3863-6.
Score: 0.262
-
JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica. 2008 Jan; 93(1):34-40.
Score: 0.261
-
Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008 Apr 15; 111(8):3931-40.
Score: 0.261
-
Update on the impact of the JAK2 mutation on signalling pathways in myeloproliferative disorders. Eur J Haematol Suppl. 2007 Oct; (68):5-8.
Score: 0.257
-
Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood. 2007 Jul 01; 110(1):375-9.
Score: 0.247
-
Functional and Structural Characterization of Clinical-Stage Janus Kinase 2 Inhibitors Identifies Determinants for Drug Selectivity. J Med Chem. 2024 06 27; 67(12):10012-10024.
Score: 0.204
-
Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms. Blood. 2023 04 27; 141(17):2127-2140.
Score: 0.189
-
Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood. 2023 04 20; 141(16):1909-1921.
Score: 0.189
-
Myeloproliferative Neoplasms: The Long Wait for JAK2-Mutant Clone Expansion. Cell Stem Cell. 2021 03 04; 28(3):359-361.
Score: 0.163
-
Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. J Clin Invest. 2019 03 04; 129(4):1596-1611.
Score: 0.142
-
The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14. Haematologica. 2019 04; 104(4):710-716.
Score: 0.139
-
HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis. Nat Commun. 2018 04 12; 9(1):1431.
Score: 0.133
-
ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation. Proc Natl Acad Sci U S A. 2015 Apr 14; 112(15):4642-7.
Score: 0.108
-
Estrogen signaling selectively induces apoptosis of hematopoietic progenitors and myeloid neoplasms without harming steady-state hematopoiesis. Cell Stem Cell. 2014 Dec 04; 15(6):791-804.
Score: 0.106
-
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014 Apr 03; 123(14):2220-8.
Score: 0.100
-
Complex subclone structure that responds differentially to therapy in a patient with essential thrombocythemia and chronic myeloid leukemia. Blood. 2013 Nov 21; 122(22):3694-6.
Score: 0.098
-
JAK2 V617F-mutated myeloproliferative neoplasia developing five years after wild-type JAK2 acute myeloid leukemia: a case report. Acta Haematol. 2013; 129(1):23-5.
Score: 0.091
-
The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat Struct Mol Biol. 2011 Aug 14; 18(9):971-6.
Score: 0.084
-
Transition to homozygosity does not appear to provide a clonal advantage to hematopoietic progenitors carrying mutations in TET2. Blood. 2011 Feb 10; 117(6):2075-6.
Score: 0.081
-
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood. 2011 Mar 10; 117(10):2813-6.
Score: 0.081
-
Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues. Leukemia. 2009 Oct; 23(10):1708-15.
Score: 0.073
-
Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status. Br J Haematol. 2009 Jul; 146(2):150-7.
Score: 0.072
-
The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. Leukemia. 2009 Oct; 23(10):1924-6.
Score: 0.072
-
Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica. 2009 Jan; 94(1):38-45.
Score: 0.069
-
NPM1-mutated acute myeloid leukaemia occurring in JAK2-V617F+ primary myelofibrosis: de-novo origin? Leukemia. 2008 Jul; 22(7):1459-63.
Score: 0.066
-
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood. 2008 Feb 01; 111(3):1686-9.
Score: 0.065
-
Advances in the understanding and management of myeloproliferative disorders. Eur J Haematol Suppl. 2007 Oct; (68):2-4.
Score: 0.064
-
Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006 Aug 15; 108(4):1377-80.
Score: 0.058
-
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood. 2005 Nov 15; 106(10):3374-6.
Score: 0.055
-
Gain of function, loss of control - a molecular basis for chronic myeloproliferative disorders. Haematologica. 2005 Jul; 90(7):871-4.
Score: 0.055
-
A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005 Apr 28; 352(17):1779-90.
Score: 0.054
-
Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosis. Nat Commun. 2023 10 12; 14(1):6414.
Score: 0.049
-
Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms. Blood. 2017 12 28; 130(26):2848-2859.
Score: 0.032
-
The leptin receptor activates janus kinase 2 and signals for proliferation in a factor-dependent cell line. Mol Endocrinol. 1997 Apr; 11(4):393-9.
Score: 0.031
-
Angiogenic factors are increased in circulating granulocytes and CD34+ cells of myeloproliferative neoplasms. Mol Carcinog. 2017 02; 56(2):567-579.
Score: 0.029
-
Stalled cerebral capillary blood flow in mouse models of essential thrombocythemia and polycythemia vera revealed by in vivo two-photon imaging. J Thromb Haemost. 2014 Dec; 12(12):2120-30.
Score: 0.026
-
Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature. 2014 Aug 07; 512(7512):78-81.
Score: 0.026
-
Dkk3 levels in patients with myeloproliferative neoplasms. Thromb Res. 2014 Feb; 133(2):218-21.
Score: 0.025
-
Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol. 2009 Nov; 6(11):627-37.
Score: 0.018
-
BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features. Leukemia. 2008 Nov; 22(11):1975-89.
Score: 0.017
-
The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood. 2006 Sep 15; 108(6):1865-7.
Score: 0.015